Placebo-controlled trial of cytisine for smoking cessation
- PMID:21991893
- DOI: 10.1056/NEJMoa1102035
Placebo-controlled trial of cytisine for smoking cessation
Abstract
Background: Cytisine, a partial agonist that binds with high affinity to the α(4)β(2) nicotinic acetylcholine receptor, is a low-cost treatment that may be effective in aiding smoking cessation. This study assessed the efficacy and safety of cytisine as compared with placebo.
Methods: We conducted a single-center, randomized, double-blind, placebo-controlled trial. Participants were randomly assigned to receive cytisine or matching placebo for 25 days; participants in both groups received a minimal amount of counseling during the study. The primary outcome measure was sustained, biochemically verified smoking abstinence for 12 months after the end of treatment. Of 1542 adult smokers screened, 740 were enrolled and 370 were randomly assigned to each study group.
Results: The rate of sustained 12-month abstinence was 8.4% (31 participants) in the cytisine group as compared with 2.4% (9 participants) in the placebo group (difference, 6.0 percentage points; 95% confidence interval [CI], 2.7 to 9.2; P=0.001). The 7-day point prevalence for abstinence at the 12-month follow-up was 13.2% in the cytisine group versus 7.3% in the placebo group (P=0.01). Gastrointestinal adverse events were reported more frequently in the cytisine group (difference, 5.7 percentage points; 95% CI, 1.2 to 10.2).
Conclusions: In this single-center study, cytisine was more effective than placebo for smoking cessation. The lower price of cytisine as compared with that of other pharmacotherapies for smoking cessation may make it an affordable treatment to advance smoking cessation globally.
Comment in
- Cytisine increased smoking cessation in adults.Zipkin DA.Zipkin DA.Ann Intern Med. 2012 Jan 17;156(2):JC1-6. doi: 10.7326/0003-4819-156-2-201201170-02006.Ann Intern Med. 2012.PMID:22250168No abstract available.
Similar articles
- Cytisine versus nicotine for smoking cessation.Walker N, Howe C, Glover M, McRobbie H, Barnes J, Nosa V, Parag V, Bassett B, Bullen C.Walker N, et al.N Engl J Med. 2014 Dec 18;371(25):2353-62. doi: 10.1056/NEJMoa1407764.N Engl J Med. 2014.PMID:25517706Clinical Trial.
- Cytisine for smoking cessation in patients with tuberculosis: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial.Dogar O, Keding A, Gabe R, Marshall AM, Huque R, Barua D, Fatima R, Khan A, Zahid R, Mansoor S, Kotz D, Boeckmann M, Elsey H, Kralikova E, Parrott S, Li J, Readshaw A, Sheikh A, Siddiqi K; TB and Tobacco Consortium.Dogar O, et al.Lancet Glob Health. 2020 Nov;8(11):e1408-e1417. doi: 10.1016/S2214-109X(20)30312-0.Lancet Glob Health. 2020.PMID:33069301Clinical Trial.
- Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR; Varenicline Phase 3 Study Group.Jorenby DE, et al.JAMA. 2006 Jul 5;296(1):56-63. doi: 10.1001/jama.296.1.56.JAMA. 2006.PMID:16820547Clinical Trial.
- Cytisine for smoking cessation: a literature review and a meta-analysis.Etter JF.Etter JF.Arch Intern Med. 2006 Aug 14-28;166(15):1553-9. doi: 10.1001/archinte.166.15.1553.Arch Intern Med. 2006.PMID:16908787Review.
- Cytisine for nicotine addiction treatment: a review of pharmacology, therapeutics and an update of clinical trial evidence for smoking cessation.Tutka P, Vinnikov D, Courtney RJ, Benowitz NL.Tutka P, et al.Addiction. 2019 Nov;114(11):1951-1969. doi: 10.1111/add.14721. Epub 2019 Jul 19.Addiction. 2019.PMID:31240783Review.
Cited by
- Study protocol for a non-inferiority trial of cytisine versus nicotine replacement therapy in people motivated to stop smoking.Walker N, Howe C, Bullen C, McRobbie H, Glover M, Parag V, Williman J, Veale R, Nosa V, Barnes J.Walker N, et al.BMC Public Health. 2011 Nov 21;11:880. doi: 10.1186/1471-2458-11-880.BMC Public Health. 2011.PMID:22104038Free PMC article.Clinical Trial.
- Design of a randomized controlled trial of smoking cessation medications for alcohol reduction among HIV-positive heavy drinkers and daily smokers in St. Petersburg, Russia.Tindle HA, Freiberg MS, Gnatienko N, Blokhina E, Cheng DM, Yaroslavtseva T, Bendiks S, Winter M, Krupitsky E, Samet JH.Tindle HA, et al.Contemp Clin Trials Commun. 2020 Jul 16;19:100625. doi: 10.1016/j.conctc.2020.100625. eCollection 2020 Sep.Contemp Clin Trials Commun. 2020.PMID:33659761Free PMC article.
- Nicotine receptor partial agonists for smoking cessation.Cahill K, Lindson-Hawley N, Thomas KH, Fanshawe TR, Lancaster T.Cahill K, et al.Cochrane Database Syst Rev. 2016 May 9;2016(5):CD006103. doi: 10.1002/14651858.CD006103.pub7.Cochrane Database Syst Rev. 2016.Update in:Cochrane Database Syst Rev. 2023 May 5;5:CD006103. doi: 10.1002/14651858.CD006103.pub8.PMID:27158893Free PMC article.Updated.Review.
- Health-care interventions to promote and assist tobacco cessation: a review of efficacy, effectiveness and affordability for use in national guideline development.West R, Raw M, McNeill A, Stead L, Aveyard P, Bitton J, Stapleton J, McRobbie H, Pokhrel S, Lester-George A, Borland R.West R, et al.Addiction. 2015 Sep;110(9):1388-403. doi: 10.1111/add.12998.Addiction. 2015.PMID:26031929Free PMC article.Review.
- The effects of noncontingent and self-administered cytisine on body weight and meal patterns in male Sprague-Dawley rats.Grebenstein PE, Harp JL, Rowland NE.Grebenstein PE, et al.Pharmacol Biochem Behav. 2013 Sep;110:192-200. doi: 10.1016/j.pbb.2013.07.012. Epub 2013 Jul 20.Pharmacol Biochem Behav. 2013.PMID:23876236Free PMC article.
Publication types
MeSH terms
Substances
Associated data
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical